体内生成CAR-T细胞治疗心脏损伤的启示与思考  

Thoughts on the CAR-T Cells Produced in Vivo to Treat Cardiac Injury

作　　者：刘光伟[1] 董瑛洁 Liu Guangwei;Dong Yingjie(College of Life Science,Beijing Normal University,Beijing 100875)

机构地区：[1]北京师范大学生命科学学院,北京100875

出　　处：《中国科学基金》2022年第1期110-112,共3页Bulletin of National Natural Science Foundation of China

摘　　要：2022年1月,美国宾夕法尼亚大学佩雷尔曼医学院的研究人员在《科学》上发表了一篇题为“CAR-T cells produced in vivo to treat cardiac injury”的研究论文,研究人员通过体内注射mRNA可以实现体内瞬时生成CAR-T细胞并用于治疗心脏损伤。CAR-T是近年来癌症免疫治疗领域的重大突破之一,在血液系统恶性肿瘤的治疗中具有广阔的发展前景。在实体瘤和其他疾病的治疗问题有待深入研究。该研究论文创新性地采用了mRNA体内注射瞬时生成CAR-T技术成功的治疗了小鼠心脏损伤,是CAR-T技术治疗肿瘤以外其他疾病的一次有效尝试。虽然该技术本身存在一定的技术限制,但是它也具有较明显的技术优势,这将为CAR-T治疗领域的研究者提供参考和借鉴。A recent paper‘CAR-T cells produced in vivo to treat cardiac injury’published on Science by Researchers from Perelman School of Medicine at the University of Pennsylvania,USA.By injecting mRNA in vivo,researchers transiently generated CAR-T cells in vivo for treating heart injury.CAR-T is one of the major breakthroughs in the field of cancer immunotherapy in recent years.It has broad development prospects in the treatment of hematological malignancies.The treatment of solid tumors and other diseases needs to be further studied.This research paper innovatively uses the transient generation CAR-T technology of mRNA injection in vivo to successfully treat mouse heart injury.It is an effective attempt of the new CAR-T technology to treat other diseases other tumors.Although the technology itself has certain technical limitations,it also has obvious technical advantages,which will provide reference for researchers in the field of CAR-T treatment.

关 键 词：免疫治疗 CAR-T 心脏损伤 

分 类 号：R730.51[医药卫生—肿瘤]